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Background: Extrapyramidal signs (EPSs) are com-
monly accepted as a feature of Alzheimer disease (AD)
and may influence both the profile of impairment and
prognosis.
Objective: To examine rates of occurrence and risk fac-
tors for all types of EPSs and to describe the impact of
EPSs over time on the clinical course of AD.
Design: Longitudinal study.
Setting: The Washington Heights Hamilton Heights In-
wood Columbia Aging Project.
Patients: A total of 388 patients with incident AD (mean
age, 79 years; 71.4% female).
Main OutcomeMeasures: Extrapyramidal signs rated
by means of a standardized portion of the Unified Par-
kinson’s Disease Rating Scale; prevalence and incidence
rates and cumulative risk for non–drug-induced EPSs;
and rates of change in EPSs over time, taking into ac-
count potential covariates.
Results: Extrapyramidal signs were detected in 12.3% of
patients at first evaluation and 22.6% at last evaluation. In
a multivariate-adjusted generalized estimating equation
modelofchange, totalEPSscore increasedatanannual rate
of1.3%.Women(relative risk[RR],1.57;P=.03),olderpa-
tients (RR, 1.03; P=.02), and those with EPSs at baseline
(RR, 2.07; P=.001) had greater rates of cognitive decline.
Conclusions: Extrapyramidal signs occur frequently and
progress significantly in AD. Patients with incident AD
and concomitant EPSs have a greater rate of cognitive de-
cline than do patients with incident AD but without EPSs.
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T HE FREQUENCY AND SEVER-ity of extrapyramidal signs(EPSs), a common featureof Alzheimer disease (AD),appear to increase over time
with disease severity.1 However, the clini-
cal significance of EPSs is poorly under-
stood because EPSs may result from dif-
ferent underlying mechanisms and location
or type of lesions. At a clinical level, they
appear to influence both profile of impair-
ment and prognosis, with several studies
showing an association between in-
creased EPSs and more severe cognitive
impairment, rapid cognitive decline, in-
stitutionalization, higher total annual cost,
and death.2-9
Most but not all previous studies were
conducted in clinic-referred patients but
not in population-based cohorts. Differ-
ences between studies with regard to di-
agnostic criteria and population sam-
pling have led to considerable variability
in prevalence estimates, which range from
6% to more than 50%.1 Prospective stud-
ies of EPSs have been rare and have gen-
erally focused on changes in specific EPSs
in individuals with established AD. Little
is currently known about the temporal re-
lationship between EPSs and AD onset, the
relative frequency of different EPSs, risk
factors for different EPS profiles, or the
manner in which specific EPSs may modu-
late clinical presentation.8,10,11
The present study is based on a com-
munity-based, prospectively observed co-
hort of incident AD cases with baseline
examinations before diagnosis. The ratio-
nale was based on the following consid-
erations: (1) the pathological changes of
AD are present in the brain many years be-
fore the clinical onset of symptoms of de-
mentia, (2) patients with AD may exhibit
evidence of motor symptoms before clini-
cal diagnosis of dementia, and (3) rates of
cognitive decline for patients with inci-
dent AD in our study were similar before
and after clinical diagnosis of dementia.
The study aimed to examine rates of oc-
currence and risk factors for all types of
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EPSs, and to describe the impact of EPSs on the rate of
the cognitive decline in a population-based cohort in
which the date of onset of dementia is known.
METHODS
PARTICIPANTS
Subjects for the present study were recruited as part of the Wash-
ington Heights Hamilton Heights Inwood Columbia Aging
Project and enrolled starting in 1992. This cohort consists
of elderly individuals identified from a probability sample of
Medicare beneficiaries who resided in an area of 3 contiguous
census tracts in northern Manhattan. Access to the names of
individuals was provided by the Health Care Financing Ad-
ministration (now the Centers for Medicare and Medicaid Ser-
vices). The proportion of individuals within each ethnic group
and age stratum who participated in the study did not differ
significantly from the source population. The study method-
ology is reported in detail elsewhere.12
The present study is based on individuals diagnosed as hav-
ing incident AD in the course of the follow-up, but who did not
have AD at baseline. We did not include individuals whose last
evaluation was the incidence one, but only those for whom we
had follow-up information after incidence. Three hundred eighty-
nine individuals from the initial cohort study met these criteria.
PROCEDURES
The study cohort was followed up during a 14-year period be-
ginning in 1992, during which time each participant received the
same medical, neurologic, and neuropsychological evaluations.
A physician elicited the medical and neurologic history of each
person and conducted a standardized physical and neurologic ex-
amination. All ancillary information (medical records, clinical in-
formation, computed tomographic scans, or magnetic reso-
nance images) was considered in the evaluation, if available.
Medical diagnoses were assigned when applicable. This exami-
nation was repeated at each follow-up. Medical history was re-
corded with specific attention to stroke, trauma, medications, and
recreational drug use. The medical comorbidities of participants
were computed by means of a modified version of the Charlson
Index of Comorbidity, which assessed conditions such as myo-
cardial infarction, congestive heart failure, peripheral vascular dis-
ease, hypertension, chronic obstructive pulmonary disease, ar-
thritis, gastrointestinal disease, mild liver disease, diabetes, chronic
renal disease, and systemic malignant disease.
A standardized neuropsychological battery comprising evalu-
ation of memory, orientation, abstract reasoning, language, and
visuospatial abilities was administered to all participants at each
follow-up. The test battery included the Selective Reminding
Test,13 the Benton Visual Retention Test,14 orientation items from
the modified Mini-Mental State Examination; the Boston Nam-
ing Test,15 verbal fluency by use of the Controlled Oral Word
Association Test, the Boston Diagnostic Aphasia Examina-
tion, the Complex Ideational Material and Repetition sub-
tests, the Wechsler Adult Intelligence Scales–Revised Similari-
ties subtest, the Mattis Dementia Rating Scale–Identities and
Oddities subtest, the Rosen Drawing Test, and the Benton Vi-
sual Retention Test. Participants were tested in English or Span-
ish according to their preference.
Participants performing below specified cutoff scores for 2
memory measures and in 2 other cognitive domains were con-
sidered to have sufficient cognitive impairment to meet cog-
nitive criteria for suspected AD. These cutoff scores have pre-
viously been shown to differentiate healthy control subjects and
patients with dementia.16 In addition to impaired cognitive per-
formance, the diagnosis of AD required impairment in social
or occupational functioning in accordance with the Diagnostic
and Statistical Manual of Mental Disorders.17 The longitudinal
study design also permitted retrospective correction of initial
AD diagnosis. Extrapyramidal signs were assessed by trained
examiners by means of a modified Unified Parkinson’s Dis-
ease Rating Scale, for which interrater reliability has already been
established.9,18
Eleven EPSs (speech, tremor at rest [in any limb], facial ex-
pression, neck rigidity, right arm rigidity, left arm rigidity, right
leg rigidity, left leg rigidity, posture, gait, and body bradykinesia/
hypokinesia) were rated on a scale of 0 to 4, with 0 being nor-
mal and 4 indicating maximum impairment. These 11 items
were then grouped into 5 domains9: speech/facial expression
(2 items; score range, 0-8), tremor (1 item; range, 0-4), rigid-
ity (5 items; range, 0-20), posture/gait (2 items; range, 0-8),
and bradykinesia (1 item; range, 0-4). A total dichotomous EPS
score was also calculated (total score2 vs total score2) as
an indicator of severity for which interrater reliability has been
demonstrated in previous studies.18 A continuous total score
was also derived from the sum of all EPS severity scores (range,
0-44). A dichotomous form (2 or2) and continuous score
were also calculated for each domain subscore. Drug-induced
EPSs were excluded from the analyses.
Information derived from the neurologic, psychiatric, and
neuropsychological assessments at each follow-up was re-
viewed by an expert consensus group comprised of neurolo-
gists and neuropsychologists. On the basis of this review, all
participants were assigned to 1 of 3 categories: dementia, mild
cognitive impairment, or normal cognitive function. Only par-
ticipants who did not have dementia at first evaluation and who
developed AD at follow-up (incident AD) were included in this
study. All procedures were approved by the institutional re-
view board at Columbia University Medical Center.
STATISTICAL ANALYSES
Baseline characteristics of patients who did and those who did
not reach the outcomes of interest during the study period were
compared by means of the t test for continuous variables and
2 test for categorical variables. We calculated the prevalence
of each EPS domain at baseline, time of incidence, and last visit.
Given the clustered nature of the data, and to use the full
range of EPS scores and characterize rates of EPS change, we
used generalized estimating equations,19 which take into ac-
count multiple visits per patient and correlations owing to re-
peated examinations. The repeated measures for each patient
are treated as a cluster. For each domain, total continuous EPS
scores were entered as the dependent variable. The main in-
dependent variable was time (years since the initial evalua-
tion). A significant time effect indicates significant changes of
EPS score over time. Models also controlled for age at base-
line, sex, education in years, and ethnicity (non-Hispanic white,
non-Hispanic black, Hispanic, and other).
To determine predictors of incident EPSs, we used Cox pro-
portional hazards analysis with total EPSs (dichotomous form)
as the outcome and duration (in years) between the initial visit
and either development of EPSs or last evaluation without EPSs
as the timing variable. Patients with EPSs at the first evalua-
tion were not included in the Cox analyses. The following pre-
dictors were included in the model: age at entry into the study,
sex, education in years, initial composite cognitive score, eth-
nicity (non-Hispanic, African American, and Hispanic), and apo-
lipoprotein E genotype. We calculated similar Cox models for
each EPS domain.
To characterize rates of cognitive changes, we also applied
generalized estimation equations to the composite cognitive
score. The composite cognitive measure was derived as fol-
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lows: each of the 12 raw scores was transformed into a z score
by means of means and standard deviations of scores from 272
controls without dementia in the Washington Heights Hamil-
ton Heights Inwood Columbia Aging Project with a similar dis-
tribution of age, education, and ethnicity to the patients with
AD. The z scores from individual tests were then averaged to
create a z score for each cognitive domain. If more than half of
the tests were missing, the domain score was considered miss-
ing and excluded from the analysis. The composite z score was
derived by averaging 5 domain scores (memory, abstract rea-
soning, visuospatial skills, language, and executive speed), with
missing data treated in the manner described earlier. The com-
posite cognitive score was entered as the dependent variable.
Independent variables were EPSs (dichotomous form), time
(years from first evaluation or at time of incidence), and
EPS time interaction. A significant EPS effect would suggest
a difference in cognitive performances at initial diagnosis for
different EPS levels. A significant time effect would suggest a
change in cognitive scores over time. A significant interaction
term would suggest differential rates of cognitive change for
different EPS levels. Models also adjusted for age at baseline,
sex, education, and ethnicity.
Finally, to determine predictors of cognitive decline, we used
Cox proportional hazards analysis with composite cognitive
score as the outcome and duration (in years) between the ini-
tial visit and either development of composite cognitive score
less than or equal to 1.5 or the last evaluation without a com-
posite cognitive score less than or equal to 1.5 as the timing
variable. Patients with a composite cognitive score less than or
equal to 1.5 at the first evaluation were not included in the Cox
analyses. The following predictors were included in the model:
age at entry into the study, sex, education in years, initial EPS
score, and ethnicity.
RESULTS
CHARACTERISTICS OF THE SAMPLE
Three hundred eighty-eight patients with incident AD
were included in the study. Basic demographic and clini-
cal characteristics are presented in Table1. Patients were
followed up for a mean (SD) of 3.6 (2.6) years, with total
follow-up times (from diagnosis to final visit or death)
ranging from 0.7 to 13.1 years and an average of 4.1 visits/
assessments per patient.
EPS DESCRIPTIVE STATISTICS
Prevalence of any EPS at baseline, time of incidence, and
final evaluation are presented in Table2. An increase was
observed across time in the frequency of all EPS domains
with the exception of resting tremor, which was also less
frequent. Similar frequencies were observed across EPS do-
mains (2.3% to 6.9% at baseline, 5.1% to 10.8% at the time
of incidence, and 7.5% to 13.6% at the final evaluation).
EPSs OVER TIME
With regard to changes across time, the generalized es-
timating equation models indicate an increase in all EPSs
Table 1. Demographic and Clinical Characteristics
Characteristic Finding
Age, mean (SD), y
At baseline 79.18 (6.91)




Education, mean (SD), y 6.9 (4.6)
1 APOE*E4 allele (n=322), % of patients 31.9
Duration of follow-up, mean (SD), y 3.6 (2.6)
No. of visits, mean (SD) 4.1 (1.8)
No. of visits after diagnosis of dementia, mean (SD) 2.7 (1.3)
Ethnicity, No. (%)
Non-Hispanic white 47 (11.9)
Non-Hispanic black 122 (31.4)
Hispanic 215 (55.4)
Other 5 (1.3)
Abbreviation: APOE*E4, apolipoprotein ε4.
Table 2. Prevalence of Each EPS at Baseline,











48 (12.3) 72 (18.5) 88 (22.6)
Speech/facial expression 9 (2.3) 20 (5.1) 32 (8.2)
Tremor at rest 5 (1.3) 7 (1.8) 6 (1.5)
Rigidity 12 (3.1) 20 (5.1) 41 (10.5)
Posture/gait 27 (6.9) 42 (10.8) 53 (13.6)
Bradykinesia 9 (2.3) 23 (5.9) 29 (7.5)
Abbreviation: EPS, extrapyramidal sign.
Table 3. Changes in EPS Score Across Time (GEE Model)a
Change From Baseline Change From Time to Incidence
 P Value  P Value
Speech/facial expression 0.068 .001 0.073 .001
Rigidity 0.192 .001 0.270 .001
Bradykinesia 0.0690 .001 0.079 .001
Posture/gait 0.103 .001 0.122 .001
Tremor 0.006 .09b 0.006 .08b
Abbreviations: EPS, extrapyramidal sign; GEE, generalized estimating equation.
aAll covariates: age, sex, education, ethnicity, and apolipoprotein E.
bNot significant.
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(continuous score) from both baseline and the time of
incidence. The rate of change was an increase of 0.4 and
0.6, respectively, in total EPS score per year of follow-
up. The results for each domain are presented in Table3.
Only tremor did not significantly increase over time from
baseline or from the time of incidence.
Another way to present these results is to calculate the
annual increase in EPS total and domain scores. From the
time of incident dementia, the annual increase in scores
was 1.30% for EPS total, 0.91% for speech/facial expres-
sion, 1.35% for rigidity, 1.97% for bradykinesia, 1.52% for


























































































































Figure. Cumulative risk (1−cumulative survival) curves of developing any extrapyramidal sign and individual domain extrapyramidal sign (y-axes). The time
axes show the time from the first evaluation until the development of motor signs (or last evaluation). A, Speech/facial expression. B, Tremor. C, Rigidity.
D, Bradykinesia. E, Posture/gait.
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The incidence and risk factors for EPS were explored
with a Cox model (Table 4). Patients with a higher cog-
nitive score at baseline were less likely to develop EPSs (any
EPS and 3 domains, including speech/facial expression, ri-
gidity, and posture/gait). Older patients were most likely
to develop EPSs (any EPS and 3 domains, such as rigidity,
posture/gait, and bradykinesia). Patients with a higher edu-
cation level were most likely to develop EPSs (any EPS and
2 domains, such as rigidity and posture/gait). Of note, there
was no influence of sex and ethnicity.
COGNITION OVER TIME
AND THE EFFECT OF EPSs ON COGNITION
We assessed the effect of EPSs on cognition (composite
cognitive score) with the generalized estimating equa-
tion model (Table 5). The presence of EPSs was associ-
ated with a lower composite cognitive score (baseline
model, =−0.224, P=.01; incidence model, =−0.165,
P=.06). Moreover, in the baseline model, patients with
tremor (=−0.300, P .001) and rigidity (=−0.407,
P .001) had lower composite cognitive scores, whereas
in the time of incidence model, impaired speech/facial ex-
pression was associated with lower composite cognitive
scores (=−0.342, P=.02). There was no significant in-
teraction with time, which indicates that the presence of
EPSs does not affect rates of cognitive decline over time.
The cognitive decline was explored with Cox models.
There were significant effects of sex (relative risk [RR], 1.57;
P=.03), age at baseline (RR, 1.03; P=.02), education (RR,
0.90;P .001), and baseline EPS score (RR, 2.07;P=.001).
Patients were thus observed to be more likely to de-
velop cognitive decline if they were female, were older
at baseline, or presented some EPS at baseline. Patients
with a higher level of education were less likely to de-
velop cognitive decline.
COMMENT
This large community-based prospective study has per-
mitted the observation of the emergence of EPSs in in-
cident AD cases. We found EPSs to be present even in
very early stages of AD, sometimes before confirmation
of the diagnosis, with their prevalence increasing over
time. Compared with other forms of EPS, resting tremor
was less frequent and did not increase over time. This
observation has also been made by previous stud-
Table 4. Cox Models Predicting Occurrence of Individual EPSs and Any EPS Overall
Variable, Risk Ratio (95% CI)
Female Sex Age Education
Composite
Cognitive Score
Speech/facial expression 0.80 (0.43-1.51) 1.01 (0.97-1.05) 1.04 (0.92-1.12) 0.57a (0.34-0.96)
Tremor 1.42 (0.52-3.83) 1.05 (0.97-1.12) 0.96 (0.84-1.09) 0.95 (0.36-2.47)
Rigidity 0.88 (0.48-1.59) 1.04a (1.01-1.08) 1.10a (1.03-1.18) 0.37a (0.23-0.59)
Posture/gait 0.65 (0.39-1.08) 1.06a (1.03-1.09) 1.07a (1.01-1.13) 0.64a (0.44-0.94)
Bradykinesia 0.57 (0.30-1.09) 1.05a (1.01-1.09) 1.07 (0.40-1.05) 0.65 (0.40-1.05)
Any EPS 0.82 (0.56-1.19) 1.05a (1.03-1.08) 1.05a (1.01-1.10) 0.58a (0.43-0.78)
Abbreviations: CI, confidence interval; EPS, extrapyramidal sign.
aSignificant association (95% CI not including 1).
Table 5. Cognition Over Time and the Effect of EPS on Cognition (GEE Model)
Baseline Model Time of Incidence Model
 P Value  P Value
Continuous Score
EPS total score −0.055 .001a 0.003 .73
Speech/facial expression −0.171 .003a −0.065 .09
Rigidity −0.115 .001a −0.008 .20
Bradykinesia −0.003 .89 0.018 .58
Posture/gait −0.103 .01a 0.109 .26
Tremor −0.138 .01a 0.113 .86
Dichotomous Score
EPS total score −0.224 .01a −0.165 .06a
Speech/facial expression −0.376 .11 −0.342 .02a
Rigidity −0.407 .001a 0.531 .03a
Bradykinesia −0.124 .55 −0.342 .08
Posture/gait −0.114 .33 0.109 .26
Tremor −0.300 .001a 0.016 .93
Abbreviations: EPS, extrapyramidal sign; GEE, generalized estimating equation.
aSignificant (P  .05) coefficients for interaction terms.
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ies.1,2,8,11,20 Symptoms of EPSs other than resting tremor
were seen to progress rapidly over time as previously
noted,1,2,10,11,20 with an annual increase in EPS scores of
0.91% to 1.97%, with only 0.15% for tremor. These cal-
culated rates are smaller or quite close to previously re-
ported ones.10,11 However, differences with regard to popu-
lation sampling and baseline levels of EPSs limit direct
comparisons.
Extrapyramidal signs and AD may share similar patho-
genesis. The presence of one increases the probability of
having the other.3,21 Whether EPSs represent the pres-
ence of AD abnormalities, Lewy body disease, or vascu-
lar disorders is still uncertain. Explanations other than
Lewy bodies for the existence of EPSs in AD include the
presence of senile plaques in the putamen, caudate, and
substantia nigra; the presence of neurofibrillary tangles
in the substantia nigra; and a neuronal loss.22,23 A main
limitation of our study is that the findings are based on
a clinical diagnosis of probable AD, without neuropatho-
logic examination.
It is important to note that EPSs may predate the clini-
cal diagnosis of dementia, as observed in previous stud-
ies. Mild parkinsonian symptoms have been described
in individuals with mild cognitive impairment.21,24 In a
French general population study,25 30% of an elderly co-
hort free of dementia were seen to have at least 1 EPS.
Their clinical significance remains unclear. Decline in ni-
grostriatal dopaminergic regulation with advancing age
is probably implicated26; however, the observed relation-
ship between EPSs and disability appears to be indepen-
dent of age, which suggests that EPSs are not a benign
feature of a normal aging process.24 They could be asso-
ciated with early cognitive symptoms in the course of
probable AD and have also been linked to depression,
possibly through common effects of underlying dopa-
minergic changes.
In our study, EPSs occurred in AD in the absence of
psychotropic medications, particularly neuroleptics. Wil-
son and MacLennan27 found no difference between id-
iopathic and iatrogenic EPSs except for a higher num-
ber of gait EPSs. With regard to difficulties in separation
of the relative contribution of neuroleptic use and AD-
related sensitivity to neuroleptics, we analyzed non–
drug-induced EPSs to increase our confidence that the
occurrence of EPSs is strictly related to an underlying dis-
ease process.
Baseline EPS symptoms were associated with lower
baseline cognitive performance, which suggests either an
early impact of the underlying neurologic changes re-
lated to EPSs on cognition or that persons with higher
performance have increased resistance to EPSs owing to
a greater number of synaptic connections that permit
longer resistance to clinical manifestations of dopamin-
ergic or serotoninergic loss.
Moreover, studies that concern the cognitive reserve
hypothesis suggest that there are individual differences
in the ability to compensate for AD lesions.28-31 Individu-
als with more cognitive reserve may have AD abnormali-
ties for a longer period before or without clinical expres-
sion.31,32 When AD changes are clinically expressed, the
disease is already quite advanced and more severe. Our
results are consistent with this hypothesis with regard
to EPSs and the level of education. Individuals with higher
educational attainment have a higher cognitive re-
serve.28,30,31 In this study, patients with a higher level of
education were most likely to develop EPSs, which may
be a hallmark of more severe disease. Furthermore, in
accordance with the previous studies, our study enables
us to validate a link between the risk of cognitive de-
cline and a more advanced age at the time of inclusion,
a lower sociocultural level, and the presence of EPSs at
the time of inclusion.
This study is one of the largest prospective studies on
a multiethnic cohort; it allows a detailed and longitudi-
nal analysis of the correlation between EPSs and cogni-
tive decline in AD. The number of incident cases led to
analyses with good statistical power and allowed us to
examine many covariates. The AD diagnosis was based
on a complete analysis of the clinical and neuropsycho-
logical data, and the final validation of AD cases was con-
ducted by a multidisciplinary expert team. The EPS evalu-
ation could be limited, because it was a subjective
assessment of the various symptoms but was based on a
short assessment scale validated in other cohort studies.
Finally, the present study confirms the association be-
tween EPSs and early AD.
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Announcement
Trial Registration Required. As a member of the Inter-
national Committee of Medical Journal Editors (ICMJE),
Archives of Neurology will require, as a condition of con-
sideration for publication, registration of all trials in a pub-
lic trials registry (such as http://ClinicalTrials.gov). Trials
must be registered at or before the onset of patient en-
rollment. This policy applies to any clinical trial starting
enrollment after July 1, 2005. The trial registration num-
ber should be supplied at the time of submission.
For details about this new policy, and for informa-
tion on how the ICMJE defines a clinical trial, see the
editorials by DeAngelis et al in the September 8, 2004
(2004;292:1363-1364) and June 15, 2005 (2005;293:
2927-2929) issues of JAMA. Also see the Instructions to
Authors on our Web site: www.archneurol.com.
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